跳至主要内容
临床试验/EUCTR2012-000979-17-DK
EUCTR2012-000979-17-DK进行中(未招募)不适用

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects with alpha-Mannosidosis - Phase III

Zymenex A/S0 个研究点目标入组 20 人开始时间: 2012年8月6日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Zymenex A/S
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities
  • 2.The subject and his/her guardian(s) must have the ability to comply with the protocol
  • 3.The subject must have a confirmed diagnosis of alpha-mannosidosis as defined by alpha-mannosidase activity < 10% of normal activity (historical data)
  • 4.The subject must have an age at the time of screening = 5 years and = 35 years
  • 5.The subject must have the ability to physically and mentally cooperate in the tests
  • 6.The subject must have an ECHO without abnormalities that, in the opinion of the Investigator, would preclude participation in the trial
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 10
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1.The subjects diagnosis cannot be confirmed by alpha-mannosidase activity < 10% of normal activity
  • 2.The subject cannot walk without support
  • 3.Presence of known chromosomal abnormality and syndromes affecting psychomotor development, other than alpha-mannosidosis
  • 4.History of BMT
  • 5.Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial
  • 6.Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial
  • 7.Pregnancy: Before start of the treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception
  • 8.Psychosis within the last 3 months
  • 9.Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial
  • 10.Participation in other interventional trials testing IMP within the last 3 months

研究者

发起方
Zymenex A/S

相似试验

A Placebo-Controlled phase 3 trial of repeated... | 临床试验